Search clinical trials for: PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine

Total 394 results

Mingzhi Zhang

Unknown

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
Hunan Cancer Hospital

Recruiting

Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

Chemotherapy Effect | NK/T-cell Lymphoma of Nasal Cavity | Immune Checkpoint Inhibitor | Epigenetic Disorder

China
Sun Yat-sen University
Bristol-Myers Squibb

Active, not recruiting

Concurrent and Adjuvant PD-1 Blockade Combined With Induction Chemotherapy Plus Radiotherapy in Nasopharyngeal Carcinoma (PLATINUM)

Nasopharyngeal Carcinoma

China
Ruijin Hospital

Recruiting

Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients

Solid Tumor

China
Sun Yat-sen University

Recruiting

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recurrent Nasopharyngeal Carcinoma

China
Dalian University

Unknown

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Non-small Cell Lung Cancer
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma (DIAMOND)

Nasopharyngeal Carcinoma

China
Peking University Third Hospital

Completed

Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer

Pancreatic Cancer | Stereotactic Body Radiotherapy | PD-1 Inhibitors

China
Southeast University, China

Unknown

Immunoregulatory Therapy for 2019-nCoV

2019 nCoV, PD-1
Sun Yat-sen University

Recruiting

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
Mingzhi Zhang

Unknown

Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Mingzhi Zhang

Unknown

PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma

NK/T Cell Lymphoma

China
Sun Yat-sen University
Chipscreen Biosciences, Ltd.

Not yet recruiting

Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR) (PCR)

Relapsed or Refractory DLBCL
Shanghai Zhongshan Hospital

Recruiting

PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery

Intrahepatic Cholangiocarcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Cholangiocarcinoma

China
Beijing Tongren Hospital

Not yet recruiting

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma, Nasal Type
Fudan University

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Advanced Thyroid Cancer Patients Who Received Target Therapy

China
Fudan University

Recruiting

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma (Sincerely20)

Peripheral T-cell Lymphoma

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaborators

Recruiting

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Surgery | PD-1

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Completed

Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

Esophageal Cancer

China
Eye & ENT Hospital of Fudan University

Not yet recruiting

Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Henlix, Inc

Unknown

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Solid Tumor

Taiwan
Nanjing Leads Biolabs Co.,Ltd

Recruiting

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Advanced Malignant Tumors

China
Sun Yat-sen University

Recruiting

Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer

Colorectal Cancer Metastatic | MSS

China
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
Bristol-Myers Squibb

Terminated

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Cancer | Neoplasm | Tumors | Malignancy

United States, Canada, Spain, Switzerland
Zhujiang Hospital

Not yet recruiting

Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world Study

Hepatocellular Carcinoma Non-resectable
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer

Uterine Cervical Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer
Chinese PLA General Hospital

Unknown

Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

Primary Mediastinal Large B-cell Lymphoma

China
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

Solid Tumor

United States
Beijing Tongren Hospital

Unknown

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

NK/T Cell Lymphoma Nos

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Lymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung Cancer

China
Cancer Hospital of Guangxi Medical University

Recruiting

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Sintilimab

China
Pfizer

Withdrawn

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer

Poland, United States
Sun Yat-sen University

Not yet recruiting

Umbrella Biomarker-Guided Therapy in NPC

Nasopharyngeal Carcinoma

China
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Nasopharyngeal Carcinoma

China
Guangzhou Gloria Biosciences Co., Ltd.

Completed

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Tianjin Medical University Cancer Institute and...

Recruiting

Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
Huiqiang Huang

Recruiting

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
Beijing Tongren Hospital

Recruiting

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma

China
Chinese PLA General Hospital

Unknown

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Nasopharyngeal Carcinoma

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Gastric Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
Chinese PLA General Hospital

Unknown

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden

China
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Relapsed/Refractory Peripheral T-cell Lymphoma

China
Chinese PLA General Hospital
Zhejiang University

Recruiting

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Lymphoma | Solid Tumor, Adult | EphA2 Overexpression | TP53 R273H | TP53 R175H | TP53 R248Q | TP53 R249S

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
Chinese PLA General Hospital
Zhejiang University

Recruiting

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Solid Tumor, Adult | KRAS G12D | EphA2 Overexpression | KRAS G12V | KRAS G12C

China

3

Subscribe